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OBJECTIVE—The mammalian target of rapamycin (mTOR)/
p70 S6 kinase 1 (S6K1) pathway is a critical signaling component
in the development of obesity-linked insulin resistance and
operates a nutrient-sensing negative feedback loop toward the
phosphatidylinositol 3-kinase (PI 3-kinase)/Akt pathway.
Whereas acute treatment of insulin target cells with the mTOR
complex 1 (mTORC1) inhibitor rapamycin prevents nutrient-
induced insulin resistance, the chronic effect of rapamycin on
insulin sensitivity and glucose metabolism in vivo remains
elusive.
RESEARCH DESIGN AND METHODS—To assess the meta-
bolic effects of chronic inhibition of the mTORC1/S6K1 pathway,
rats were treated with rapamycin (2 mg/kg/day) or vehicle for 15
days before metabolic phenotyping.
RESULTS—Chronic rapamycin treatment reduced adiposity
and fat cell number, which was associated with a coordinated
downregulation of genes involved in both lipid uptake and
output. Rapamycin treatment also promoted insulin resistance,
severe glucose intolerance, and increased gluconeogenesis. The
latter was associated with elevated expression of hepatic glu-
coneogenic master genes, PEPCK and G6Pase, and increased
expression of the transcriptional coactivator peroxisome prolif-
erator–activated receptor- coactivator-1 (PGC-1) as well as
enhanced nuclear recruitment of FoxO1, CRTC2, and CREB.
These changes were observed despite normal activation of the
insulin receptor substrate/PI 3-kinase/Akt axis in liver of rapam-
ycin-treated rats, as expected from the blockade of the mTORC1/
S6K1 negative feedback loop.
CONCLUSIONS—These ﬁndings unravel a novel mechanism by
which mTORC1/S6K1 controls gluconeogenesis through modula-
tion of several key transcriptional factors. The robust induction
of the gluconeogenic program in liver of rapamycin-treated rats
underlies the development of severe glucose intolerance even in
the face of preserved hepatic insulin signaling to Akt and despite
a modest reduction in adiposity. Diabetes 59:1338–1348, 2010
T
he mammalian target of rapamycin (mTOR) is a
Ser/Thr kinase that belongs to the phosphatidyl-
inositol (PI) kinase-related protein kinase family
(1). mTOR integrates signals from growth fac-
tors, hormones, nutrients, and cellular energy level to
regulate protein translation and cell growth, proliferation,
and survival (1). mTOR exists in two complexes. The
mTOR complex 1 (mTORC1) is composed of mTOR, GL,
PRAS40, deptor, and raptor and regulates cell growth,
whereas the complex 2 (mTORC2) consists of mTOR,
GL, protor-1, mSIN1, deptor, and rictor and controls
cytoskeleton regulation and cell survival (1,2). mTORC1
activates cellular processes by phosphorylating two down-
stream effectors, p70 S6 kinase 1 (S6K1) and eukaryotic
initiation factor 4E-binding protein 1 (4E-BP1) (3). Both
mTORC1 and S6K1 are activated by insulin through the
insulin receptor/insulin receptor substrate (IRS)/phospha-
tidylinositol 3-kinase (PI 3-kinase)/Akt pathway (4). We
and others have shown that chronic activation of the
mTORC1/S6K1 pathway by nutrients or prolonged insulin
treatment promotes insulin resistance through increased
IRS-1 serine phosphorylation, leading to a reduction in
IRS-1 function and impaired activation of the PI 3-kinase/
Akt pathway, thereby creating a negative feedback loop on
insulin action. Accordingly, acute inhibition of mTORC1
by rapamycin was found to restore insulin action on the PI
3-kinase/Akt pathway and to prevent the insulin-resistant
effects of excess nutrients on insulin-mediated glucose
transport in muscle and adipose cells (3,5–7).
Because rapamycin protects from insulin resistance
caused by excess nutrients in vitro, it was proposed that it
may hold promise as a drug for treatment of insulin
resistance in obesity. In fact, rapamycin is already used in
the clinic as an effective immunosuppressant in human
transplant recipients to prevent graft rejection (8). How-
ever, somewhat paradoxically it appears that a signiﬁcant
side effect of chronic inhibition of mTORC1/S6K1 signaling
by rapamycin treatment is deranged lipid and glucose
metabolism (9). Indeed chronic rapamycin administration
was found to cause hyperlipidemia and to reduce fat mass,
as well as to promote glucose intolerance and a diabetes-
like syndrome (8,10,11). However, the underlying mecha-
nisms behind these metabolic derangements remain
unknown and particularly intriguing when considering
that rapamycin exerts positive metabolic actions when
used in vitro in insulin target cells.
In the present study, we have evaluated the effects of
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tial mechanisms by which this mTORC1 inhibitor impacts
on lipid and glucose metabolism. We show that rapamycin
treatment reduces fat deposition in white adipose tissue
through altered expression of key enzymes required for
fatty acid uptake and triglyceride synthesis. Despite such loss
in fat mass, rapamycin treatment also causes insulin resis-
tance and glucose intolerance, in part through inducing
hepatic gluconeogenesis by enhancement of the expression
of gluconeogenic enzymes and nuclear recruitment of impor-
tant gluconeogenic transcriptional regulators. This hepatic
phenotype was observed despite preservation of insulin
signaling through the IRS/PI 3-kinase/Akt pathway as ex-
pected from the ability of rapamycin to block the mTORC1/
S6K1-dependent phosphorylation of IRS-1 on serine residues.
Our data thus provide a mechanism to explain the higher
prevalence of glucose intolerance and a diabetes-like syn-
drome in rapamycin-treated patients who underwent a trans-
plant and further highlight the importance of the mTORC1/
S6K1 pathway in modulating glucose homeostasis.
RESEARCH DESIGN AND METHODS
Animals. Animal handling and treatment were approved by the Animal Care
and Handling Committee of Laval University. Male Sprague-Dawley rats (200
g) were purchased from Charles River Laboratories (St. Constant, QC,
Canada) and housed individually in cages in a room kept at 23  1°C with a
12-h light/12-h dark cycle. After 4-day adaptation, rats were matched by weight
and divided into control and rapamycin-treated groups. Vehicle (0.1% Me2SO,
0.2% carboxymethylcellulose) or rapamycin (2 mg/kg/day; Biomol, Plymouth-
Meeting, PA) was injected intraperitoneally once daily. Because the mTORC1
complex acts as a cellular nutrient sensor, we performed experiments (except
where indicated) on rats that had been fasted for 12 h followed by3ho f
refeeding to achieve physiological activation of insulin signaling. After 15 days
of treatment, control and rapamycin-treated rats were killed by decapitation.
Tissues and blood were rapidly harvested and frozen in liquid nitrogen.
Intraperitoneal glucose, insulin, and pyruvate tolerance tests. Rats
were fasted for 6 h and injected intraperitoneally with glucose (2 g/kg) or
insulin (2.5 units/kg; human insulin; Eli Lilly, Toronto, ON, Canada) diluted in
saline 0.9%. For the pyruvate tolerance test, rats were fasted for 12 h and refed
for 3 h before being injected with pyruvate (2 g/kg; Sigma-Aldrich, Oakville,
ON, Canada) diluted in saline 0.9%. Blood was collected from the tail tip prior
to and at various times after injection.
Plasma/tissue determinations. Blood glucose levels were measured by a
Precision PCx glucometer (MediSense; Abbott Laboratories, Mississauga, ON,
Canada). Plasma insulin, C-peptide, and glucagon were determined by radio-
immunoassay (Linco Research, St. Charles, MO). Plasma adiponectin and
leptin were measured by ELISA following the suppliers’ recommendations
(ALPCO Diagnostics, Salem, NH; Millipore, Nepean, ON, Canada). Triglycer-
ides in plasma and in muscle/liver lipid extracts (Roche Diagnostics, Montreal,
QC, Canada) and nonesteriﬁed fatty acids (WakoChemicals, Richmond, VA),
glycerol (Sigma-Aldrich), and lactate (Eton Bioscience, Hayward, CA) levels
were measured by enzymatic methods according to the manufacturers’
instructions.
Immunoblotting and immunoprecipitation. Tissue samples were homog-
enized in buffer, subjected to SDS-PAGE, and transferred to nitrocellulose
membranes as previously described (3). For immunoprecipitation of IRS-1
and IRS-2, liver samples were homogenized in buffer (20 mmol/l Tris, pH 7.5,
140 mmol/l NaCl, 1% Nonidet P-40, 2 mmol/l Na4P2O7, 10 mmol/l NaF, 2 mmol/l
Na3VO4, and protease inhibitors). Equal amounts of protein (1 mg) were
immunoprecipitated with protein A–Sepharose and subjected to SDS-PAGE as
described above. Antibodies used for immunoblotting are listed in supplemen-
tal Table 1, available in an online appendix at http://diabetes.diabetesjournals.
org/content/early/2010/03/10/db09-1324/suppl/DC1. Densitometric analysis
was performed with ImageQuant TL software (GE Healthcare, Little Chalfont,
U.K.).
Nuclear extracts. Liver nuclear extracts were prepared as previously
described (12) and submitted to immunoblotting as described above.
Kinase assays. PI 3-kinase activity was measured in IRS-1 or IRS-2 immuno-
precipitates, and Akt kinase activity was measured in Akt immunoprecipitates
as previously described using a commercial peptide (crosstide) (3).
RNA extraction and quantitative PCR analysis. RNA extraction and
quantitative PCR analysis were performed as described previously (13). The
primers used are listed in supplemental Table 2. Data are expressed as the
ratio between the expression of the target gene and the housekeeping gene
36B4 (also known as ARBP), the expression of which was not signiﬁcantly
affected by treatment.
Adipose tissue DNA content and adipocyte diameter. Adipocyte diameter
was measured as described previously (14). Tissue DNA content was deter-
mined using the DNeasy tissue kit (QIAGEN, Mississauga, ON, Canada)
following the manufacturer’s instructions.
Morphometric analysis of islets. Islet size and -cell mass were measured
as previously described (15).
MIN6 cells. MIN6 cells at 70% conﬂuence were seeded in 24-well plates 1 day
before treatments. On the day of the experiment, cells were incubated for 2 h
in Krebs-Ringer bicarbonate HEPES buffer containing 2.8 mmol/l glucose
before incubation for 2.5–30 min at 10 mmol/l glucose. Culture medium was
collected and assayed for insulin content by ELISA (ALPCO Diagnostics).
Statistical analysis. ANOVA was performed using the general linear model
procedure of Statistical Analysis Software (SAS, Version 9.2; SAS Institute,
Cary, NC). When appropriate, initial body weight was included in the
statistical model as a covariate.
RESULTS
Chronic rapamycin treatment reduces adiposity and
causes hyperlipidemia. Rapamycin treatment signiﬁ-
cantly reduced (86%) body weight gain, which could be
partly attributed to reduced (15%) food intake (Table 1).
Rapamycin also decreased food efﬁciency by 84% and
plasma leptin levels by 52%, suggesting that the weight-
reducing effect of the drug is explained mostly by in-
creased energy expenditure (Table 1). This is consistent
with the recent ﬁnding that disruption of adipose mTORC1
signaling through raptor knockout increased energy ex-
penditure (16). Accordingly, we found that rapamycin did
not affect the amount of feces calories per gram of food
ingested, indicating that intestinal lipid absorption was not
TABLE 1
Effect of 15-day rapamycin treatment on weight, food intake, and
metabolic parameters of treated rats
Control Rapamycin
Body weight (g) 303.6  3.68 226.3  4.34***
Weight gain (g) 91.4  3.57 12.8  3.87***
Food intake (g) 256.4  6.53 217.7  8.53**
Food efﬁciency (body weight
gain/food intake) 0.117  0.004 0.019  0.006***
Glucose (mmol/l) 8.5  0.33 13.3  2.53*
Insulin (pmol/l) 351.5  58.7 1,265.1  395.1*
Glucagon (ng/l) 127.25  10.65 130.47  14.33
Triglycerides (mmol/l) 0.644  0.050 0.848  0.060*
NEFAs (mmol/l) 0.115  0.020 0.190  0.040*
Glycerol (mg/dl) 1.025  0.084 1.177  0.107
Lactate (mmol/l) 0.904  0.050 0.852  0.039
Adiponectin (g/ml) 11.89  1.53 12.11  0.83
Leptin (ng/ml) 9.48  1.86 4.94  1.51*
Data are average  SE (n  12 control, n  10 for rapamycin). Refed
plasma data are average  SE (n  6–12 for control, n  6–10 for
rapamycin). *P  0.05, **P  0.01, ***P  0.001 vs. control. NEFAs,
nonesteriﬁed fatty acids.
TABLE 2
Effect of 15-day rapamycin treatment on muscle and liver
triglycerides
Control Rapamycin
Muscle triglycerides
(mmol/g tissue) 9.52  0.92 10.40  0.93
Liver triglycerides
(mmol/g tissue) 18.69  4.02 12.94  0.95
Data are average  SE (n  6 for each group).
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absolute mass of all tissues sampled was signiﬁcantly
decreased in rapamycin-treated rats (supplementary Table
3) on a relative mass basis (tissue mass/body weight), only
white adipose tissue was signiﬁcantly reduced compared
with control rats, suggesting that rapamycin treatment
preferentially impaired adipogenesis beyond its effect on
body growth (supplementary Table 3 and Fig. 1A). This is
supported by both the strong tendency toward smaller
adipocyte diameter (P  0.057, Fig. 1B and C) and
signiﬁcantly fewer adipocytes (lower DNA content per
depot, Fig. 1B and C) in the rapamycin-treated group
relative to control. In line with these observations, chronic
rapamycin treatment increased plasma triglycerides (32%)
and nonesteriﬁed fatty acids (65%) (Table 1), suggesting
that adipose triglyceride deposition was impaired.
Because clinical studies have reported that rapamycin
treatment causes hyperlipidemia and reduces body fat
mass, it was deemed important to explore the potential
underlying mechanisms by which the mTORC1 inhibitor
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FIG. 1. Chronic rapamycin treatment decreases adiposity. Sprague-Dawley rats were treated with vehicle or rapamycin (2 mg/kg/day) for 15 days.
A: Relative retroperitoneal fat weight. Total DNA tissue content and adipocyte diameter (m) (B) and representative images of retroperitoneal
fat (C) from control and rapamycin-treated rats (magniﬁcation 10) D: Representative Western blots of adipose tissue lysates are shown for
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with total Akt antibody. Immunoprecipitates were analyzed for Akt activity. The graphs depict densitometric analysis of total Akt activity. n 
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mTORC1 and, more recently, raptor have been shown to
control adipogenesis (17) through Akt-mediated phosphor-
ylation of tuberous sclerosis complex 2 (18). However,
although rapamycin is rather selective for mTORC1, pro-
longed treatment with the drug can also inhibit mTORC2
and Akt (19). We thus explored whether chronic rapamy-
cin treatment decreased adipogenesis indirectly through
inhibition of mTORC2 and Akt. As expected, the phosphor-
ylation of S6 (Ser240/244), a downstream substrate of the
mTORC1/S6K1 pathway, was blunted in adipose tissue by
rapamycin (Fig. 1D). Furthermore, Akt phosphorylation
on Ser473 was severely inhibited in rapamycin-treated rats
(Fig. 1D) indicating that mTORC2 may also have been
inhibited by chronic drug exposure. In contrast, however,
Akt Thr308 phosphorylation was not decreased in adipose
tissue of rapamycin-treated rats (Fig. 1D) and Akt kinase
activity was actually increased (Fig. 1E), suggesting that
phosphorylation on Thr308 more than compensates for the
reduction in Ser473 phosphorylation. This is supported by
the fact that phosphorylation of the Akt substrate glycogen
synthase kinase-3 (GSK-3) was not reduced in adipose
tissue of rapamycin-treated rats (Fig. 1D). Thus, chronic
rapamycin administration likely affected adiposity via
mTORC1 but not mTORC2 inhibition.
Chronic rapamycin treatment coordinately down-
regulates genes required for lipid uptake and storage
in adipose tissue. To better understand the mechanism
by which chronic rapamycin treatment impairs adipogen-
esis and causes hyperlipidemia, we next measured the
mRNA levels of several genes involved in the clearance of
lipids from the circulation and their deposition in adipose
tissue as triglycerides. Retroperitoneal adipose tissue ex-
pression of lipoprotein lipase (LPL), which catalyzes the
hydrolysis of lipoprotein-bound triglycerides supplying
fatty acids and glycerol for adipose depot uptake (20),
along with the fatty acid transporters (FATP1 and FAT/
CD36) were all downregulated by rapamycin treatment
(Fig. 2). In addition, phosphoenolpyruvate carboxykinase
(PEPCK), which generates the glycerol 3-phosphate back-
bone for fatty acid esteriﬁcation (21), and lipin 1, an
important enzyme involved in triglyceride synthesis (22),
were also signiﬁcantly reduced by rapamycin treatment.
We also evaluated the mRNA levels of the enzymes adi-
pose triglyceride lipase (ATGL), hormone-sensitive lipase
(HSL), and monoacyglycerol lipase (MGL), which catalyze
the sequential hydrolysis of triglycerides to fatty acids and
glycerol (23). Chronic rapamycin treatment markedly re-
duced the expression of ATGL and MGL without affecting
those of HSL, excluding possible participation of in-
creased lipolysis to the adipose tissue phenotype and
hyperlipidemia. Interestingly, the reduced expression of
genes involved in lipid uptake and storage and lipolysis
was associated with a signiﬁcant decrease in the mRNA
levels of peroxisome proliferator-activated receptor-2
(PPAR2), a master regulator of adipogenesis, lipogenesis,
and lipolysis (Fig. 2) (13,20,24).
Chronic rapamycin treatment impairs glucose toler-
ance, -cell mass, insulin clearance, and insulin sen-
sitivity and results in higher expression of crucial
elements of the gluconeogenic pathway in the liver.
Treatment with rapamycin markedly affected glucose and
insulin homeostasis as reﬂected by hyperglycemia and
hyperinsulinemia (Table 1). Furthermore, rapamycin led
to an exaggerated response to glucose administration
during a glucose tolerance test, indicative of impaired
glucose tolerance (Fig. 3A). The insulin levels during the
glucose tolerance test were very high in the rapamycin-
treated group and did not return to basal levels as they did
in the control group (Fig. 3B). The glycemic response to
insulin was also reduced in rapamycin-treated rats (Fig.
3C). However, plasma adiponectin, glucagon, glycerol, and
lactate were not altered by the inhibitor (Table 1). The
insulin response during the glucose tolerance test sug-
gested a possible defect in islet function. Indeed, as shown
in Fig. 4A, islet histology showed that rapamycin-treated
rats had more small islets and fewer large islets compared
with control rats as well as reduced -cell mass (Fig. 4B).
Nevertheless, plasma C-peptide levels were unchanged 3 h
after refeeding, although the elevated ratio of insulin/C-
peptide suggests that a marked impairment of hepatic
insulin clearance underlies the hyperinsulinemic state of
rapamycin-treated rats (Fig. 4C and D). To test whether
rapamycin directly affected -cell function, we also tested
the effect of the drug on glucose-induced insulin secretion
in MIN6 cells but found no alterations (Fig. 4E).
Given the severity of glucose intolerance, we ﬁrst fo-
cused on the contribution of the liver to the diabetes-like
phenotype of rapamycin-treated rats. We studied the
mRNA and protein expression of transcriptional regula-
tors of hepatic gluconeogenesis and key enzymes under
their control. Notably, chronic rapamycin treatment re-
sulted in greatly elevated liver expression of PPAR
coactivator-1 (PGC-1) mRNA as well as higher expres-
sion of the two key gluconeogenic enzymes, PEPCK and
glucose-6-phosphatase (G6Pase) (Fig. 5A). Nuclear lo-
calization of forkhead box O1 (FoxO1), PGC-1, cAMP
response element-binding protein (CREB)–regulated
transcription coactivator 2 (CRTC2; also known as
TORC2), and CREB was also signiﬁcantly enhanced after
chronic rapamycin treatment (Fig. 5B). We also performed
a pyruvate tolerance test to provide functional evidence
that the increased gluconeogenic gene expression was
associated with elevated gluconeogenesis. As shown in
Fig. 5C, the blood glucose level of rapamycin-treated rats
was different from control rats for the last 90 min of the
test, suggesting increased hepatic gluconeogenesis. Nei-
ther liver glycogen (data not shown) nor triglyceride
(Table 2) content was altered by rapamycin treatment. To
conﬁrm that rapamycin could directly alter hepatic glu-
cose metabolism, we treated FAO hepatoma cells with
rapamycin for 24 h and observed a marked augmentation
of glucose production in the basal state as well as in the
presence of insulin (supplementary Fig. 1A and B).
Chronic rapamycin treatment improves insulin sig-
naling despite enhancing hepatic gluconeogenesis.
Insulin inhibits hepatic glucose production at least in part
through its ability to bind and activate the insulin receptor,
leading to the phosphorylation of IRS proteins and subse-
quent activation of PI 3-kinase and Akt. Because Akt
negatively modulates hepatic gluconeogenesis through
phosphorylation of FoxO1 (25), it was of major interest to
test whether insulin signaling to Akt was impaired in the
liver of rapamycin-treated rats. We found, however, that
rapamycin-mediated inhibition of the mTORC1/S6K1 path-
way, as revealed by complete loss of S6 Ser240/244 phos-
phorylation, improved insulin signaling in the liver, as
shown by increased tyrosine phosphorylation of both
IRS-1 and IRS-2 (Fig. 6A) and, conversely, diminished
inhibitory phosphorylation of IRS-1 on serine residues
(Ser1101 and Ser636/639) (Fig. 6B). IRS-1 and IRS-2 pro-
tein expression was also increased in the liver of rapam-
V.P. HOUDE AND ASSOCIATES
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insulin signaling cascade, we found that hepatic IRS-1
(P  0.01)– and IRS-2 (P  0.06)–associated PI 3-kinase
activity was increased by rapamycin (Fig. 6D), whereas
Akt phosphorylation on Ser473 and Thr308 as well as Akt
kinase activity were not affected (Fig. 6E and F). We also
found that tyrosine phosphorylation of IRS-1 was in-
creased (Fig. 6G), whereas Akt kinase activity was not
affected (Fig. 6H) in skeletal muscle of rapamycin-treated
rats. Moreover, rapamycin treatment did not affect muscle
triglyceride content (Table 2).
DISCUSSION
The mTORC1/S6K1 pathway has recently emerged as a
critical signaling component in the development of obesity-
linked insulin resistance by operating a negative feedback
loop toward PI 3-kinase/Akt through increasing inhibitory
serine phosphorylation of IRS-1 (4–6,26). Accordingly, we
and others have demonstrated that acute treatment with
rapamycin in vitro prevents nutrient-induced insulin resis-
tance by interfering with this negative feedback loop and
limiting phosphorylation of IRS-1 on multiple serine resi-
dues (3,5,7,27). Moreover, we recently reported that S6K1
plays a key role in hepatic insulin action through phos-
phorylation of both Ser1101 and Ser636/639 in hepatic
cells and liver of obese insulin-resistant high-fat–fed mice
(6). Other studies have shown that long-term activation of
the mTORC1/S6K1 pathway also promotes insulin resis-
tance through the proteasomal degradation of IRS-1 (28)
and IRS-2 (29). In the present study, we found that chronic
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FIG. 2. Chronic rapamycin treatment coordinately downregulates
genes required for triglyceride hydrolysis, fatty acid transport, and
esteriﬁcation in adipose tissue. Rats were treated with rapamycin as
described in the legend to Fig. 1, and adipose tissue was sampled and
processed as described in the RESEARCH DESIGN AND METHODS section for
determinations of LPL, FATP1, FAT/CD36, Lipin1, PEPCK, MGL,
HSL, ATGL, PPAR1, and PPAR2 mRNA expression. The graphs
depict mRNA expression in the adipose tissue of target genes cor-
rected for the expression of 36B4 as a control gene. n  12 for each
group. *P < 0.05, **P < 0.01.
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to IRS/PI 3-kinase and maintains activation of Akt in the
liver, in agreement with our previous ﬁndings in hepato-
cytes acutely treated with the drug (4). Accordingly, we
found that chronic inhibition of the mTORC1/S6K1 path-
way in rats increases IRS-1 and IRS-2 protein expression,
enhances their tyrosine phosphorylation while reducing
IRS-1 inhibitory phosphorylation on Ser1101 and Ser636/
639. This led to upregulation of IRS-dependent PI 3-kinase
activation and normal Akt activity in liver, despite the
development of severe whole-body glucose intolerance
and insulin resistance. This apparent uncoupling between
hepatic insulin signaling and glucose homeostasis is in
large part explained by augmented gluconeogenesis, un-
raveling a novel mechanism of regulation of hepatic glu-
cose production by the mTORC1/S6K1 pathway.
Liver gluconeogenesis is driven by the availability of
gluconeogenic substrates and the activity of two important
gluconeogenic enzymes, PEPCK and G6Pase (30). In the
refed state, insulin suppresses gluconeogenesis by tran-
scriptional downregulation of PEPCK and G6Pase (31).
Our data indicate that rapamycin upregulates gluconeo-
genesis in the refed state by increasing the expression of
PEPCK and G6Pase. This was observed despite hyperin-
sulinemia and without any change in the concentrations of
circulating glucagon or major gluconeogenic substrates.
We also found that rapamycin markedly increases PGC-1
mRNA expression, which likely contributes to the upregu-
lation of the gluconeogenic enzymes, as observed in type 2
diabetes (32). Because rapamycin blocks a major nutrient-
sensing pathway, it has been suggested that it mimics a
starvation-like signal even in the presence of nutrients (33)
and as such could explain the increase in PGC-1 expres-
sion. This is the ﬁrst report of PGC-1 regulation by
mTORC1/S6K1 in liver but recent studies have linked this
nutrient-sensing pathway to PGC-1 and the regulation of
skeletal muscle metabolism (34–36).
PGC-1 increases gluconeogenic gene expression at
least in part by coactivating transcription by FoxO1 (37),
possibly through its ability to target O-GlcNAc transferase
for GlcNAcylation of FoxO1 (38). Conversely, insulin
suppresses gluconeogenesis through Akt-dependent phos-
phorylation of FoxO1, leading to its nuclear exclusion and
degradation (39). We found that chronic rapamycin treat-
ment increases FoxO1 nuclear content where it activates
the transcription of PEPCK and G6Pase (40). Thus, FoxO1
nuclear exclusion was not observed, despite the presence
of hyperinsulinemia and the maintenance of normal he-
patic insulin signaling to Akt in rapamycin-treated rats.
Further studies will be needed to test whether rapamycin
increases gluconeogenic gene transcription via a PGC1-
dependent GlcNAcylation of FoxO1, thus bypassing insu-
lin-induced Akt activation and phosphorylation of FoxO1.
Interestingly, rapamycin treatment increases nuclear
recruitment of both CREB and CRTC2. In response to
glucagon and other cAMP-elevating hormones, CRTC2
binds to CREB and stimulates the gluconeogenic program
by triggering the dephosphorylation and nuclear translo-
cation of CRTC2, whereas insulin blunts this process
through activation of salt-inducible kinase 2, which phos-
phorylates and induces the cytoplasmic translocation and
proteasomal degradation of CRTC2 (41,42). CREB may
also promote gluconeogenesis through increased PGC-1
expression (43). The observation that both nuclear CRTC2
and FoxO1 remained elevated 3 h after refeeding in the
liver of rapamycin-treated rats likely explains the robust
activation of gluconeogenesis in these animals. A recent
study by Liu et al. (44) has demonstrated the existence of
a temporal switch from CRTC2 to FoxO1 as a critical
inducer of gluconeogenesis during a prolonged fast. This
switch is operated by a complex series of acetylation and
deacetylation events that affect stability and activity of
both CRTC2 and FoxO1. The fact that both of these
redundant transcriptional factors are activated even after
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FIG. 3. Chronic rapamycin treatment induces glucose and insulin
intolerance in rats. Rats were treated with rapamycin as described in
the legend to Fig. 1 and fasted for 6 h before intraperitoneal tolerance
tests. Plasma glucose (A) and insulin levels (B) were measured during
a glucose tolerance test. C: Plasma glucose levels were measured
during an insulin tolerance test. n  12 for each group. Black squares:
CTRL; white squares: RAP. *P < 0.05, **P < 0.01, ***P < 0.001.
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a fully operative hepatic insulin signaling pathway, sug-
gests that mTORC1/S6K1 exerts a previously unsuspected
powerful control over the gluconeogenic program.
We also found that rats treated chronically with rapa-
mycin have a decreased -cell mass. This is consistent
with recent reports that chronic activation of mTOR leads
to -cell mass expansion (15,45). Despite the reduced
-cell mass, insulin secretion as revealed by C-peptide
levels after refeeding was not altered in rapamycin-treated
rats, suggesting that their hyperinsulinemic state is ex-
plained rather by impaired hepatic insulin clearance. Al-
though the reduced -cell mass could explain the lack of
further insulin release during the glucose tolerance test,
two observations suggest that the liver defects precede the
development of -cell dysfunction in this model. First, we
found that liver gluconeogenesis was affected already after
only 2 days of rapamycin treatment (supplementary Fig. 2)
even before hyperglycemia develops. Second, insulin se-
cretion by MIN6 cells is not altered by rapamycin treat-
ment for up to 48 h. Nevertheless, the reduction in -cell
mass suggests that chronic exposure to rapamycin may
eventually cause major perturbations in -cell function
and further contribute to the diabetes-like syndrome in-
duced by the mTOR inhibitor.
Reduced accretion of body fat and hyperlipidemia con-
stitute another important phenotypic feature of rapamy-
cin-treated rats. The inhibitor appears to affect adiposity
mainly through a reduction in cell number, with a small
contribution from reduced adipocyte size. This is consis-
tent with studies in cell lines in which chronic rapamycin
treatment or small interfering RNA–mediated downregula-
tion of either mTOR, raptor, or S6K1 can have direct effects
on adipogenesis and lipid content (17,46,47). The gene ex-
pression data suggest a robust reduction in lipid ﬂux in and
out of adipose tissue. Hence, the coordinated downregula-
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FIG. 4. Chronic rapamycin treatment impairs -cell
mass and insulin clearance in rats. Rats were treated
with rapamycin as described in the legend to Fig. 1.
Pancreatic sections were stained with an antibody
against insulin for the determination of islet size and
-cell mass as described in the RESEARCH DESIGN AND
METHODS section. A: Size distribution of islets ex-
pressed as percentage of total islets. n  10 for each
group. B: Pancreatic -cell mass. n  6 for each
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insulin over C-peptide, a measure of insulin clear-
ance. n  12 for each group. E: Insulin secretion was
determined in MIN6 cells treated with rapamycin (25
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hydrolysis (LPL), cellular uptake (FAT/CD36 and FATP1),
and storage of lipid (PEPCK and lipin), all known to impact
adiposity (48), appeared to be counterbalanced by the down-
regulation of lipolytic (ATGL, MGL) enzyme expression,
consistent with the near maintenance of cell size in rapamy-
cin-treated rats. Reduced lipid uptake and fat cell number
impairs the capacity of adipose tissue for plasma lipid
clearance, which likely contributes to hyperlipidemia.
Several lines of evidence suggest that the rapamycin-
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genes in adipose tissue might be the result of a reduced
transcriptional activity of PPAR. Indeed, all such genes
are known to be positively modulated by PPAR
(13,20,24). Furthermore, rapamycin inhibits PPAR tran-
scriptional activity in adipocytes (46), and adipose-speciﬁc
disruption of raptor in mice reduces adiposity (16). Con-
versely, activation of mTORC1 increases PPAR expres-
sion in adipocytes (18). In the present study, rapamycin
reduced the expression of both PPAR2 and lipin 1, a key
lipogenic enzyme and PPAR coactivator (22). Collec-
tively, these congruent ﬁndings strongly suggest a molec-
ular link between mTORC1 and PPAR transcriptional
activity.
We also considered the possibility that the effects of
rapamycin on PPAR expression and adipogenesis might
be linked to secondary inhibition of mTORC2, leading to a
reduction of Akt activation. However, the reduced Akt
Ser473 phosphorylation was possibly compensated by
normal phosphorylation of Thr308 because Akt kinase
activity and GSK-3 phosphorylation were not reduced in
adipose tissue of rapamycin-treated rats. GSK-3 phosphor-
ylation was recently found to be preserved despite com-
plete loss of Akt Ser473 phosphorylation in mouse embryo
ﬁbroblasts from rictor knockout animals (49). Our conclu-
sion that mTORC2 inhibition cannot account for the
reduction of adiposity is also supported by recent studies
in mice with adipose tissue–speciﬁc disruption of rictor
and mTORC2 signaling, which failed to reduce adipogen-
esis or fat mass in chow-fed animals (50).
In conclusion, chronic inhibition of the mTORC1/S6K1
pathway by rapamycin causes glucose intolerance mainly
through inducing transcriptional activation of gluconeo-
genic genes via the coordinated activation of PGC-1,
CRTC2, CREB, and FoxO1. The robust activation of the
gluconeogenic program was observed even under hyper-
insulinemia in the refed state, and despite the maintenance
of normal activation of hepatic insulin signaling to Akt
owing to the blockade of the mTORC1/S6K1 inhibitory
feedback loop by rapamycin. The mTORC1 inhibitor has
also marked effects on lipid deposition in adipose tissues
that likely contribute to elevated concentrations of plasma
triglycerides and nonesteriﬁed fatty acids. Our ﬁndings
therefore further emphasize the critical importance of the
mTORC1/S6K1 pathway in the physiological regulation of
glucose and lipid metabolism and unravel a new role for
this nutrient-sensing pathway in the control of hepatic
gluconeogenesis through the modulation of several key
transcription factors of the gluconeogenic program. This
unrestrained activation of hepatic gluconeogenesis likely
underlies the occurrence of a diabetes-like syndrome in
patients treated with rapamycin.
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